Square Pharmaceuticals (DHA:SQURPHARMA) Moat Score: 0/10 (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:SQURPHARMA Square Pharmaceuticals PLC DHA:SQURPHARMA
94 GF Score
Price BDT214.70
GF Value BDT219.96
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Square Pharmaceuticals Moat Score?

Square Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Square Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Square Pharmaceuticals might have No Moat - No discernible moat.

Square Pharmaceuticals  (DHA:SQURPHARMA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Square Pharmaceuticals Moat Score Related Terms

DHA:SQURPHARMA
94GF Score
Square Pharmaceuticals PLC DHA:SQURPHARMA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued. The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96. GuruFocus considers Square Pharmaceuticals to be Fairly Valued.

Key valuation signals for DHA:SQURPHARMA:

  • Moat Score: 0
  • GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Square Pharmaceuticals Business Description

Address Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score

Get the complete analysis for DHA:SQURPHARMA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT214.70
Price
BDT219.96
GF Value